These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 18610847)
21. How does MYCN amplification make neuroblastomas behave aggressively? Still more questions than answers. Maris JM Pediatr Blood Cancer; 2005 Dec; 45(7):869-70. PubMed ID: 16206200 [No Abstract] [Full Text] [Related]
22. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Combaret V; Audoynaud C; Iacono I; Favrot MC; Schell M; Bergeron C; Puisieux A Cancer Res; 2002 Jul; 62(13):3646-8. PubMed ID: 12097268 [TBL] [Abstract][Full Text] [Related]
23. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465 [TBL] [Abstract][Full Text] [Related]
24. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Slack A; Lozano G; Shohet JM Cancer Lett; 2005 Oct; 228(1-2):21-7. PubMed ID: 15927364 [TBL] [Abstract][Full Text] [Related]
25. The prognostic role of urinary catecholamines in infants with disseminated neuroblastoma may be mediated by MYCN amplification. Parodi S; Papio F; Haupt R; Conte M; De Bernardi B Pediatr Blood Cancer; 2007 May; 48(5):593; author reply 593-4. PubMed ID: 16937359 [No Abstract] [Full Text] [Related]
26. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458 [TBL] [Abstract][Full Text] [Related]
28. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model. Blanc E; Goldschneider D; Ferrandis E; Barrois M; Le Roux G; Leonce S; Douc-Rasy S; Bénard J; Raguénez G Am J Pathol; 2003 Jul; 163(1):321-31. PubMed ID: 12819037 [TBL] [Abstract][Full Text] [Related]
29. MYCN haploinsufficiency is associated with reduced brain size and intestinal atresias in Feingold syndrome. van Bokhoven H; Celli J; van Reeuwijk J; Rinne T; Glaudemans B; van Beusekom E; Rieu P; Newbury-Ecob RA; Chiang C; Brunner HG Nat Genet; 2005 May; 37(5):465-7. PubMed ID: 15821734 [TBL] [Abstract][Full Text] [Related]
30. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228 [TBL] [Abstract][Full Text] [Related]
31. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. Paffhausen T; Schwab M; Westermann F Cancer Lett; 2007 May; 250(1):17-24. PubMed ID: 17141950 [TBL] [Abstract][Full Text] [Related]
32. Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification. Kushner BH; LaQuaglia MP; Modak S; Cheung NK Med Pediatr Oncol; 2003 Jul; 41(1):80-2. PubMed ID: 12764755 [No Abstract] [Full Text] [Related]
33. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation. Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814 [TBL] [Abstract][Full Text] [Related]
34. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR. Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822 [TBL] [Abstract][Full Text] [Related]
35. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304 [TBL] [Abstract][Full Text] [Related]
36. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification. Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419 [TBL] [Abstract][Full Text] [Related]
37. Enhanced expression of MYCN leads to centrosome hyperamplification after DNA damage in neuroblastoma cells. Sugihara E; Kanai M; Matsui A; Onodera M; Schwab M; Miwa M Oncogene; 2004 Jan; 23(4):1005-9. PubMed ID: 14647433 [TBL] [Abstract][Full Text] [Related]
38. Keratoepithelin reverts the suppression of tissue factor pathway inhibitor 2 by MYCN in human neuroblastoma: a mechanism to inhibit invasion. Becker J; Volland S; Noskova I; Schramm A; Schweigerer LL; Wilting J Int J Oncol; 2008 Jan; 32(1):235-40. PubMed ID: 18097563 [TBL] [Abstract][Full Text] [Related]
39. Prognostic value of MYCN and ID2 overexpression in neuroblastoma. Alaminos M; Gerald WL; Cheung NK Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351 [TBL] [Abstract][Full Text] [Related]
40. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line. Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]